Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Edition Issue on the “Pathogenesis and Treatment of Chronic Pruritus” contains an overview of various known causes of chronic pruritus and emerging therapeutics. Chronic pruritus is an itch that lasts longer than six weeks, and is associated with a variety of dermatologic, systemic, neurologic, and psychiatric etiologies. Itch negatively impacts patient quality of life, and has devastating psychosocial consequences. The manuscripts published in this Special Issue are also a showcase of the current understanding of the pathogenesis of chronic pruritus, along with its epidemiology, diagnostic workup, and therapeutic approaches used to treat chronic pruritus. A special focus is also placed on prurigo nodularis, a severely pruritic chronic inflammatory skin disease.

Medicine --- dupilumab --- IL-4 --- IL-13 --- pruritus --- chronic pruritus of unknown origin --- prurigo nodularis --- uremic pruritus --- lichen planus --- eosinophilic dermatosis of hematologic malignancy --- chronic pruritus --- mirtazapine --- chronic --- itch --- refractory --- treatment --- noradrenergic --- serotonergic --- antihistaminergic --- antidepressant --- skin --- atopic dermatitis --- ceramide --- pine tar --- drug-induced --- medication-related --- epidemiology --- inpatient --- disease burden --- national inpatient sample --- medical dermatology --- systematic review --- prurigo --- nodularis --- atopic --- dermatitis --- race --- gender --- comorbidities --- demographics --- pediatric --- children --- malignancy --- cancer --- neoplasm --- ion channels --- cell signaling --- Cav3.2 calcium channel --- RT-PCR --- wounds --- itch in wounds --- itch management --- aprepitant --- erlotinib --- EGFR --- epidermal growth factor receptor --- NK1R --- neurokinin1-receptor --- mycosis fungoides --- psoriasis --- associations --- lymphomatoid papulosis --- lymphoma --- racial differences --- nodular prurigo --- neuropathy --- therapeutic --- pathogenesis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Edition Issue on the “Pathogenesis and Treatment of Chronic Pruritus” contains an overview of various known causes of chronic pruritus and emerging therapeutics. Chronic pruritus is an itch that lasts longer than six weeks, and is associated with a variety of dermatologic, systemic, neurologic, and psychiatric etiologies. Itch negatively impacts patient quality of life, and has devastating psychosocial consequences. The manuscripts published in this Special Issue are also a showcase of the current understanding of the pathogenesis of chronic pruritus, along with its epidemiology, diagnostic workup, and therapeutic approaches used to treat chronic pruritus. A special focus is also placed on prurigo nodularis, a severely pruritic chronic inflammatory skin disease.

Medicine --- dupilumab --- IL-4 --- IL-13 --- pruritus --- chronic pruritus of unknown origin --- prurigo nodularis --- uremic pruritus --- lichen planus --- eosinophilic dermatosis of hematologic malignancy --- chronic pruritus --- mirtazapine --- chronic --- itch --- refractory --- treatment --- noradrenergic --- serotonergic --- antihistaminergic --- antidepressant --- skin --- atopic dermatitis --- ceramide --- pine tar --- drug-induced --- medication-related --- epidemiology --- inpatient --- disease burden --- national inpatient sample --- medical dermatology --- systematic review --- prurigo --- nodularis --- atopic --- dermatitis --- race --- gender --- comorbidities --- demographics --- pediatric --- children --- malignancy --- cancer --- neoplasm --- ion channels --- cell signaling --- Cav3.2 calcium channel --- RT-PCR --- wounds --- itch in wounds --- itch management --- aprepitant --- erlotinib --- EGFR --- epidermal growth factor receptor --- NK1R --- neurokinin1-receptor --- mycosis fungoides --- psoriasis --- associations --- lymphomatoid papulosis --- lymphoma --- racial differences --- nodular prurigo --- neuropathy --- therapeutic --- pathogenesis --- dupilumab --- IL-4 --- IL-13 --- pruritus --- chronic pruritus of unknown origin --- prurigo nodularis --- uremic pruritus --- lichen planus --- eosinophilic dermatosis of hematologic malignancy --- chronic pruritus --- mirtazapine --- chronic --- itch --- refractory --- treatment --- noradrenergic --- serotonergic --- antihistaminergic --- antidepressant --- skin --- atopic dermatitis --- ceramide --- pine tar --- drug-induced --- medication-related --- epidemiology --- inpatient --- disease burden --- national inpatient sample --- medical dermatology --- systematic review --- prurigo --- nodularis --- atopic --- dermatitis --- race --- gender --- comorbidities --- demographics --- pediatric --- children --- malignancy --- cancer --- neoplasm --- ion channels --- cell signaling --- Cav3.2 calcium channel --- RT-PCR --- wounds --- itch in wounds --- itch management --- aprepitant --- erlotinib --- EGFR --- epidermal growth factor receptor --- NK1R --- neurokinin1-receptor --- mycosis fungoides --- psoriasis --- associations --- lymphomatoid papulosis --- lymphoma --- racial differences --- nodular prurigo --- neuropathy --- therapeutic --- pathogenesis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.

Humanities --- Social interaction --- virus-like particle --- influenza A(H1N1)pdm09 --- vaccination --- pregnant women --- antibody titers --- norovirus --- VLP --- vaccine --- genotype --- pre-existing immunity --- cross-reactivity --- blocking antibodies --- original antigenic sin (OAS) --- HPVs --- vaccines --- virus-like particles (VLPs) --- minor capsid protein (L2) --- HCMV --- cytomegalovirus --- nanoparticle --- immune response --- Sudan virus --- mice --- horse --- purified IgG --- long-lived plasma cells --- antibodies --- multivalency --- virus-like particles --- antigenic analysis --- epitope characterization --- hepatitis E vaccine --- serological evaluation --- virion-like epitopes --- well-characterized vaccines --- hepatitis B virus --- surface (envelope) antigen --- sub-viral particle --- capsid --- antigen display --- platform --- viral quantification --- NTA --- flow virometry --- SRFM --- cryo-TEM --- SEM --- plant virus --- virus-like --- vaccine platform --- epitope --- antigen --- cat allergy --- Fel d 1 --- HypoCat™ --- IL-13 --- interleukin-13 --- Tfh cells --- cancer --- immunotherapy --- H7N9 --- pandemic influenza A --- avian flu --- IAV --- VLP vaccine --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.

Technology: general issues --- drug delivery into the brain --- transendothelium based on receptor-mediated transcytosis --- immunotherapy --- Alzheimer’s disease --- anti-tau and anti-receptor bispecific monoclonal antibodies --- Alzheimer’s disease-relevant tau species --- temporal-spatial pathological Aβ and tau distribution --- interactions between Aβ and tau --- tau clearance in microglia --- tau clearance in neurons --- liposome --- nanoparticle --- seizure --- laser --- ultrasound --- naringenin --- nanostructured lipid carrier --- intranasal delivery --- central composite rotatable design --- depression --- pomegranate seed oil --- nasal delivery system --- memory impairment --- movement impairment --- delivery to brain --- improved memory --- phospholipid oily gel --- high-grade glioma --- diffuse midline glioma --- glioblastoma --- IL-13Rα2 --- IL-13 --- immunotoxin --- targeted therapy --- GB-13 --- IL13.E13K-PE4E --- receptor expression --- acetaminophen --- blood–brain barrier --- claudin-5 --- CNS drug delivery --- opioids --- tight junction --- microdialysis --- cerebral open flow microperfusion --- electrochemical biosensors --- macromolecules --- tolcapone --- microparticles --- nanoparticles --- PLGA --- Parkinson’s disease --- nose to brain delivery --- gene therapy --- polyplexes --- hyaluronidase --- glycol chitosan --- brain cancer --- chemoattractant --- CXCL --- CXCR --- glioblastoma multiforme --- 3D cell culture systems --- non-human primate --- convection-enhanced delivery --- neurosurgery --- optogenetics --- blood-brain barrier --- brain targeted therapy --- drug delivery --- cerebrospinal fluid microcirculation --- brain biodistribution --- n/a --- Alzheimer's disease --- Alzheimer's disease-relevant tau species --- Parkinson's disease